Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the ac...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4981355?pdf=render |
| _version_ | 1817990287412166656 |
|---|---|
| author | Fumitaka Haseda Akihisa Imagawa Hiroyoshi Nishikawa Shinobu Mitsui Chiharu Tsutsumi Reiko Fujisawa Hiroyuki Sano Yuko Murase-Mishiba Jungo Terasaki Shimon Sakaguchi Toshiaki Hanafusa |
| author_facet | Fumitaka Haseda Akihisa Imagawa Hiroyoshi Nishikawa Shinobu Mitsui Chiharu Tsutsumi Reiko Fujisawa Hiroyuki Sano Yuko Murase-Mishiba Jungo Terasaki Shimon Sakaguchi Toshiaki Hanafusa |
| author_sort | Fumitaka Haseda |
| collection | DOAJ |
| description | Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D. |
| first_indexed | 2024-04-14T00:57:17Z |
| format | Article |
| id | doaj.art-69bc76783763486f8f395002dcf1e483 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T00:57:17Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-69bc76783763486f8f395002dcf1e4832022-12-22T02:21:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016057610.1371/journal.pone.0160576Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.Fumitaka HasedaAkihisa ImagawaHiroyoshi NishikawaShinobu MitsuiChiharu TsutsumiReiko FujisawaHiroyuki SanoYuko Murase-MishibaJungo TerasakiShimon SakaguchiToshiaki HanafusaFulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the acute and 1 in the sub-acute phases from each patient) by seromic analysis. Second, titres of the antibody were measured by ELISA in sera from 30 patients with FT1D (both in the acute and sub-acute phases), 13 patients with FT1D in the chronic phase, 32 patients with autoimmune type 1 (type 1A) diabetes (T1AD), 30 patients with type 2 diabetes (T2D), 23 patients with autoimmune thyroid disease (AITD) and 31 healthy control subjects (HC).Seromic analysis revealed 9 antibodies which showed high signals from all 3 patients with FT1D in the acute phase. Among them, the titre of anti-CD300e antibody was significantly higher in FT1D patients in the acute phase than that in T1AD, T2D, AITD patients and HC, as determined by ELISA (P<0.01, respectively). The titre of anti-CD300e antibody was also higher in FT1D in the acute phase than that in the sub-acute phase (P = 0.0018, Wilcoxon signed-rank test). The titre of anti-LGALS3 antibody in FT1D patients in the acute phase did not differ from that in patients with FT1D in the sub-acute phase, T1AD, T2D, AITD and HC.The titre of a novel antibody, anti-CD300e, was high in sera from patients with FT1D. This antibody might be a diagnostic marker and provide new insight into the pathogenesis of FT1D.http://europepmc.org/articles/PMC4981355?pdf=render |
| spellingShingle | Fumitaka Haseda Akihisa Imagawa Hiroyoshi Nishikawa Shinobu Mitsui Chiharu Tsutsumi Reiko Fujisawa Hiroyuki Sano Yuko Murase-Mishiba Jungo Terasaki Shimon Sakaguchi Toshiaki Hanafusa Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. PLoS ONE |
| title | Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
| title_full | Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
| title_fullStr | Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
| title_full_unstemmed | Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
| title_short | Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. |
| title_sort | antibody to cmrf35 like molecule 2 cd300e a novel biomarker detected in patients with fulminant type 1 diabetes |
| url | http://europepmc.org/articles/PMC4981355?pdf=render |
| work_keys_str_mv | AT fumitakahaseda antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT akihisaimagawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT hiroyoshinishikawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT shinobumitsui antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT chiharutsutsumi antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT reikofujisawa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT hiroyukisano antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT yukomurasemishiba antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT jungoterasaki antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT shimonsakaguchi antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes AT toshiakihanafusa antibodytocmrf35likemolecule2cd300eanovelbiomarkerdetectedinpatientswithfulminanttype1diabetes |